Therapie最新文献

{"title":"Are there gender differences in adverse drug reactions to levodopa? A real-world safety comparison in the global pharmacovigilance database","authors":"Jean-Louis Montastruc","doi":"10.1016/j.therap.2025.11.004","DOIUrl":"10.1016/j.therap.2025.11.004","url":null,"abstract":"<div><h3>Background</h3><div>Gender differences were reported in Parkinson's disease as well as in drug effects in general.</div></div><div>Gender differences were reported in Parkinson's disease as well as in drug effects in general.</div><div><h3>Objective</h3><div>The study was performed to investigate putative gender differences in levodopa-related adverse drug reactions (ADRs).</div></div><div>The study was performed to investigate putative gender differences in levodopa-related adverse drug reactions (ADRs).</div><div><h3>Methods</h3><div>Using Vigibase®, the global pharmacovigilance database, all ADRs reports with levodopa between 01/01/2000 and 31/12/2024 in adults were included. The main levodopa (motor and non-motor) ADRs were compared between women and men. Results are presented as reporting odds ratios (ROR) with their 95% confidence interval.</div></div><div>Using Vigibase®, the global pharmacovigilance database, all ADRs reports with levodopa between 01/01/2000 and 31/12/2024 in adults were included. The main levodopa (motor and non-motor) ADRs were compared between women and men. Results are presented as reporting odds ratios (ROR) with their 95% confidence interval.</div><div><h3>Results</h3><div>Among 2887 ADRs with levodopa, the reporting risk in women was significantly higher for dyskinesia (ROR<!--> <!-->=<!--> <!-->1.31 [1.00–1.71]), dystonia (1.41 [1.03–1.93]), nausea-vomiting (2.08 [1.45–2.99]), and significantly lower for hypersexuality (0.10 [0.02–0.42]), dopamine dysregulation syndrome (0.32 [0.14–0.73]) pathological gambling (0.33 [0.14–0.76]) and all ADRs in general (0.48 [0.45–0.52]), with no difference for other ADRs.</div></div><div>Among 2887 ADRs with levodopa, the reporting risk in women was significantly higher for dyskinesia (ROR<!--> <!-->=<!--> <!-->1.31 [1.00–1.71]), dystonia (1.41 [1.03–1.93]), nausea-vomiting (2.08 [1.45–2.99]), and significantly lower for hypersexuality (0.10 [0.02–0.42]), dopamine dysregulation syndrome (0.32 [0.14–0.73]) pathological gambling (0.33 [0.14–0.76]) and all ADRs in general (0.48 [0.45–0.52]), with no difference for other ADRs.</div><div><h3>Conclusion</h3><div>This study shows gender-related differences for not only motor (dyskinesia, dystonia) but also non-motor levodopa ADRs.</div></div><div>This study shows gender-related differences for not only motor (dyskinesia, dystonia) but also non-motor levodopa ADRs.</div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"81 4","pages":"Pages 318-322"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145726096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebral air embolism induced by polidocanol foam sclerotherapy in chronic venous disease: A case report","authors":"Gwendal Dubois,&nbsp;Charles Khouri,&nbsp;Christophe Seinturier,&nbsp;Sophie Blaise","doi":"10.1016/j.therap.2025.11.005","DOIUrl":"10.1016/j.therap.2025.11.005","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"81 4","pages":"Pages 358-361"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145744363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application de la méthode REB dans l’évaluation de l’intérêt thérapeutique des anti-inflammatoires non stéroïdiens par voie orale et topique dans la prise en charge de la douleur aiguë liée aux traumatismes de l’appareil locomoteur","authors":"François Lacour,&nbsp;Nicolas Criscito,&nbsp;Rémy Boussageon","doi":"10.1016/j.therap.2025.10.005","DOIUrl":"10.1016/j.therap.2025.10.005","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Les traumatismes aigus de l’appareil locomoteur correspondent à un motif de consultation fréquent en soins primaires. Les anti-inflammatoires non stéroïdiens (AINS) sont couramment prescrits dans ce contexte. Des méta-analyses récentes témoignent d’une balance bénéfice–risque favorable aux AINS topiques et de l’absence de supériorité des AINS per os en termes de soulagement de la douleur en comparaison avec le paracétamol seul ou en association. Dans ce contexte, il semble nécessaire d’évaluer plus rigoureusement la balance bénéfice–risque des AINS afin de mener à des recommandations plus consensuelles et de promouvoir un usage approprié et raisonné de cette classe médicamenteuse en traumatologie.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Les traumatismes aigus de l’appareil locomoteur correspondent à un motif de consultation fréquent en soins primaires. Les anti-inflammatoires non stéroïdiens (AINS) sont couramment prescrits dans ce contexte. Des méta-analyses récentes témoignent d’une balance bénéfice–risque favorable aux AINS topiques et de l’absence de supériorité des AINS per os en termes de soulagement de la douleur en comparaison avec le paracétamol seul ou en association. Dans ce contexte, il semble nécessaire d’évaluer plus rigoureusement la balance bénéfice–risque des AINS afin de mener à des recommandations plus consensuelles et de promouvoir un usage approprié et raisonné de cette classe médicamenteuse en traumatologie.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;div&gt;L’objectif de cette étude est d’évaluer l’efficacité et la balance bénéfice–risque des AINS per os et topiques dans la prise en charge de la douleur aiguë des traumatismes mineurs, en réalisant une revue systématique de la littérature avec méta-analyse des essais contrôlés randomisés (ECR) selon la méthode « Rebuild the Evidence Base » (REB).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;L’objectif de cette étude est d’évaluer l’efficacité et la balance bénéfice–risque des AINS per os et topiques dans la prise en charge de la douleur aiguë des traumatismes mineurs, en réalisant une revue systématique de la littérature avec méta-analyse des essais contrôlés randomisés (ECR) selon la méthode « Rebuild the Evidence Base » (REB).&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Matériels et méthodes&lt;/h3&gt;&lt;div&gt;Une revue systématique de la littérature a été effectuée dans les bases de données Medline (PubMed), CENTRAL (Cochrane) et Embase. Les ECR évaluant les AINS per os et topiques (diclofénac, ibuprofène, kétoprofène et naproxène) dans le traitement de la douleur aiguë des traumatismes mineurs ont été inclus. Ils sont issus des références bibliographiques de la méta-analyse de Busse et al. de janvier 2020 ainsi que d’une recherche bibliographique complémentaire de janvier 2020 à décembre 2023. Le critère de jugement principal est la douleur à court terme (de 30&lt;!--&gt; &lt;!--&gt;minutes à 7&lt;!--&gt; &lt;!--&gt;jours). Les critères de jugements secondaires sont la douleur au repos et la douleur au mouvement, à j3 en priorité et à différents temps d’évaluation en cas de","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"81 4","pages":"Pages 329-345"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intranasal abuse of buspirone: Cases serie","authors":"Quentin Tourdot,&nbsp;Margot Lestienne,&nbsp;Paul Mathieu,&nbsp;Thomas Risdorfer De Issdentzi,&nbsp;Coralie Bourzeix,&nbsp;Laura Jaubert,&nbsp;Hélène Donnadieu,&nbsp;Céline Eiden,&nbsp;Hélène Peyrière","doi":"10.1016/j.therap.2025.11.001","DOIUrl":"10.1016/j.therap.2025.11.001","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"81 4","pages":"Pages 352-355"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145565499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hydroxyurea-induced severe interstitial pneumonitis: A case report","authors":"Omar Masrour,&nbsp;Roya Nili Asgari,&nbsp;Anne Charpentier,&nbsp;Olivier Sanchez,&nbsp;Jean Pastre","doi":"10.1016/j.therap.2025.11.003","DOIUrl":"10.1016/j.therap.2025.11.003","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"81 4","pages":"Pages 355-358"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145679010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Multi-batch analysis of a slimming dietary supplement adulterated with sibutramine: Report of three toxicovigilance cases].","authors":"Thomas Schiestel, Laurine Le Visage, Pauline Limoges, Romain Magny, Laurence Labat, Jérôme Langrand, Pascal Houzé","doi":"10.1016/j.therap.2026.06.002","DOIUrl":"https://doi.org/10.1016/j.therap.2026.06.002","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148424356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacology of pruritus (pathophysiology, therapeutic targets).","authors":"Emilie Brenaut, Laurent Misery","doi":"10.1016/j.therap.2026.06.001","DOIUrl":"https://doi.org/10.1016/j.therap.2026.06.001","url":null,"abstract":"<p><p>Pruritus (itch) is defined as an unpleasant sensation provoking the urge to scratch and can be understood both as a symptom and, when lasting more than six weeks, as a disease entity termed chronic pruritus (CP). CP is characterized by complex neurobiological changes and can persist independently of the initial trigger, significantly impairing quality of life. Advances since the 1990s in understanding itch pathophysiology have led to the development of numerous targeted therapies, although many treatments remain off-label. Pruritus is classified into dermatological, systemic, neuropathic, and psychogenic categories, often with overlapping etiologies. Effective management prioritizes identifying and treating the underlying cause. Pathophysiologically, itch originates from specialized peripheral sensory neurons (pruriceptors), which transmit signals through histaminergic and non-histaminergic pathways. While histamine plays a role mainly in urticaria, chronic itch is largely mediated by non-histaminergic mechanisms involving cytokines, neuropeptides, proteases, transient receptor potential (TRP) channels, and Mas-related G-protein-coupled receptors (MRGPRs). Keratinocytes, mast cells, and immune mediators such as IL-31, IL-4, and IL-13 actively participate in itch signaling, creating neuroimmune feedback loops. Peripheral and central sensitization, spinal disinhibition, and altered pain-itch interactions sustain chronic itch and the itch-scratch cycle, particularly in chronic prurigo (CPG), a distinct disease model for CP. Therapeutic strategies target multiple levels of itch processing. Traditional treatments include antihistamines, topical anesthetics, calcineurin inhibitors, antidepressants, gabapentinoids, and immunosuppressants, though efficacy varies. Recent breakthroughs include biologics targeting TH2 pathways (dupilumab, nemolizumab), JAK inhibitors, κ-opioid receptor agonists (difelikefalin), and IBAT inhibitors (for cholestatic pruritus). Novel targets under investigation include MRGPRs, PARs, KIT receptors, OX-40, and sodium channels.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148340475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Self-medication and its factors amongst Navymen aboard surface ships of the French Navy at sea: A descriptive study].","authors":"Hugo Le Claire, Nicolas Robin, Bakridine Mmadi Mrenda, Ludovic Karkowski","doi":"10.1016/j.therap.2026.05.002","DOIUrl":"https://doi.org/10.1016/j.therap.2026.05.002","url":null,"abstract":"<p><strong>Aims: </strong>The objective of this study was to assess the prevalence and determinants of self-medication among military personnel deployed on surface ships of the French Navy.</p><p><strong>Methods: </strong>A cross-sectional observational monocentric study was conducted from April to September 2024 using self-administered questionnaires distributed on board five surface ships from the Toulon naval base. The data collected covered sociodemographic characteristics and self-medication behaviors. Statistical analyses were performed using R software (version 4.0.3; 2020).</p><p><strong>Results: </strong>Among the 405 participants included, 54.1% reported having used at least one medication in self-medication during the mission. First-line painkillers were the most commonly used drugs (85.8%), mainly for headaches (82.2%). Independent predictive factors for self-medication were female sex, being a crew member or petty officer over 25 years old, longer mission duration, and history of self-medication practices. Adverse drug reactions were reported by 2.8% of participants.</p><p><strong>Conclusion: </strong>Self-medication appears to be a common practice among naval personnel, probably favored by isolation, culture of the performance, and desire to maintain operational skills. These findings highlight the need for better education and supervision regarding self-medication use at sea, the development of guidelines for a reasonable self-medication, and a stronger preventive role for onboard medical staff.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148056955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to prescribing methylphenidate for adults with ADHD: A qualitative study.","authors":"Diane Lafarge, Joël Charbit, Antoine Lamer, Margot Trimbur, Louise Carton","doi":"10.1016/j.therap.2026.05.001","DOIUrl":"https://doi.org/10.1016/j.therap.2026.05.001","url":null,"abstract":"<p><strong>Context: </strong>Attention deficit/hyperactivity disorder (ADHD) affects approximately 2.5% of the adult population. In France, the pharmacological management of adults with ADHD is mainly based on methylphenidate, a medication for which the initial prescription and annual renewal must be carried out by a specialist such as a psychiatrist or a neurologist. Despite the high prevalence of this disorder, the prescription of methylphenidate by psychiatrists remains limited. We therefore aimed to explore the barriers to prescribing methylphenidate by psychiatrists for adults with ADHD.</p><p><strong>Method: </strong>A qualitative study using semistructured individual interviews was conducted between June and July 2025 with psychiatrists working in the Hauts-de-France region, France. The data were transcribed, coded and analyzed using a thematic approach.</p><p><strong>Results: </strong>Ten psychiatrists were interviewed, with a diversity of profiles in terms of age and type of practice. Three main themes emerged as barriers to prescribing. First, participants reported a lack of knowledge about the disorder and its management. Second, they described uncertainty regarding possible differential diagnoses, as well as therapeutic constraints in the presence of psychiatric or substance use comorbidities. Finally, they highlighted the time-consuming nature of the diagnosis and management of this disorder. Other aspects were also mentioned including delays in accessing cardiology consultations, some patients' reluctance regarding drug treatment, the occurrence of adverse drug reactions, and medication shortages.</p><p><strong>Conclusion: </strong>In light of the identified barriers, strengthening professional training, providing adult-specific prescribing guidelines, and structuring the care pathway appear to be key levers to improve access to care.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148176795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple HIV virological failures related to bictegravir-valproic acid interaction evidenced by therapeutic drug monitoring: A retrospective study.","authors":"Jennifer Lagoutte-Renosi, Marie-Blanche Valnet Rabier, Simona Berbescu, Fabienne Bozon, Jakub Kowalczyk, Anne-Sophie Brunel, Axel Ursenbach, Pierre Gantner, Quentin Lepiller, Damien Montange, Siamak Davani, Patrice Muret","doi":"10.1016/j.therap.2026.04.006","DOIUrl":"https://doi.org/10.1016/j.therap.2026.04.006","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148035062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}